YOKOHAMA, Japan, Oct 17 (Bernama-GLOBE NEWSWIRE) -- Today’s press conference at the International Association for the Study of Lung Cancer (IASLC) 18th
World Conference on Lung Cancer (WCLC) featured groundbreaking findings
in the study of both small cell and non-small cell lung cancer. The
studies presented covered broad research areas, from confirmation of
existing classification criteria to ensuring viability of evidence to
supporting the use of specific interventions.
Biopsy specimen found to be reliable for evaluating DLL3 expression in small cell lung cancer
Small
cell lung cancer (SCLC) biopsy specimen was found to be reliable
material for evaluating DLL3 expression; high levels of DLL3 in SCLC are
correlated with poor survival trends. These results may lead to further
evaluation of the scoring system for predicting DLL3-targeted
therapeutic efficacy and clinical significance of DLL3 expression in
high-grade pulmonary neuroendocrine carcinomas. Dr. Li-Xu Yan of
Guangdong General Hospital and Guangdong Academy of Medical Sciences in
China presented her findings in today’s press conference. Read the full
press release here.
Treatment
based on BRCA1 expression levels does not increase survival rate of
stage II and III non-small cell lung cancer N+ resected patients
Dr.
Bartomeu Massuti of Alicante University Hospital in Spain on behalf the
Spanish Lung Cancer Cooperative Group (GECP-SCLG) shared new research
that shows that treating stage II and III non-small cell lung cancer
(NSCLC) N+ resected patients with customized chemotherapy (CT) treatment
based on their specific BRCA1 expression levels, as opposed to
providing the standard treatment, did not increase overall survival
rates among those patients who received individualized CT treatment.
However, BRCA1 expression levels could be prognostic and treatment could
achieve different outcomes. Find the full press release here.
Researchers confirm IASLC proposed characterization of uncertain R status R(un), with prognosis between R0 and R1
The
findings of a recent study, presented by Dr. John Edwards of the
University of Sheffield in the UK, confirm proposed criteria from the
International Association for the Study of Lung Cancer (IASLC) for
uncertain resection margin status, R(un), in residual tumor (R)
classification. The researchers undertook this study to analyze R status
criteria using data collected from the IASLC Lung Cancer Staging
Project. The full press release is available here.
PACIFIC
study shows quality of life is maintained in non-small cell lung cancer
patients treated with durvalumab after concurrent chemoradiation
The
use of the immunotherapy drug durvalumab after concurrent
chemoradiation in locally advanced, unresectable non-small cell lung
cancer (NSCLC) patients was shown to improve progression-free survival
(PFS) while upholding quality of life measures, according to new
research from Dr. Rina Hui of the University of Sydney and Westmead
Hospital in Australia. The results of the study showed that patients
treated with durvalumab did not experience worsening of symptoms,
function or health-related quality of life, which was similar to
patients who received placebo. The full press release can be found here.
Livestreams of the daily press conferences are available here.
About the WCLC
The
World Conference on Lung Cancer (WCLC) is the world’s largest meeting
dedicated to lung cancer and other thoracic malignancies, attracting
over 6,000 researchers, physicians and specialists from more than 100
countries. The goal is to disseminate the latest scientific
achievements; increase awareness, collaboration and understanding of
lung cancer; and to help participants implement the latest developments
across the globe. Organized under the theme of “Synergy to Conquer Lung
Cancer,” the conference will cover a wide range of disciplines and
unveil several research studies and clinical trial results. For more
information, visit wclc2017.iaslc.org.
About the IASLC
The
International Association for the Study of Lung Cancer (IASLC) is the
only global organization dedicated to the study of lung cancer and other
thoracic malignancies. Founded in 1974, the association's membership
includes more than 6,500 lung cancer specialists across all disciplines
in over 100 countries, forming a global network working together to
conquer lung and thoracic cancers worldwide. The association also
publishes the Journal of Thoracic Oncology, the primary educational and
informational publication for topics relevant to the prevention,
detection, diagnosis and treatment of all thoracic malignancies. Visit www.iaslc.org for more information.
Contacts:
Hillary Wasserman
Senior Associate
HWasserman@GroupGordon.com
+1 732-778-1896
Becky Bunn, MSc
Public Relations Manager
Becky.Bunn@IASLC.org
+1 720-254-9509
SOURCE : IASLC
No comments:
Post a Comment